Last reviewed · How we verify
Crowd Health Research, LTD — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Epithelium-Off Riboflavin | Epithelium-Off Riboflavin | phase 3 | Corneal cross-linking agent | Corneal collagen (indirect via riboflavin photosensitization) | Ophthalmology | |
| Epithelium-On Riboflavin | Epithelium-On Riboflavin | phase 3 | Corneal cross-linking agent | Corneal collagen (photochemical cross-linking via riboflavin and UVA) | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Cornea and Laser Eye Institute · 1 shared drug class
- Icahn School of Medicine at Mount Sinai · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Crowd Health Research, LTD:
- Crowd Health Research, LTD pipeline updates — RSS
- Crowd Health Research, LTD pipeline updates — Atom
- Crowd Health Research, LTD pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Crowd Health Research, LTD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/crowd-health-research-ltd. Accessed 2026-05-16.